News und Analysen
Transgene Presents Promising New Data from its Next-Generation Immunotherapy Platforms at AACR 2020
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presents its broad viral vector expertise and their
Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDA
Regulatory News:
“With our recent Fast Track designation for NBTXR3 in this patient population, acceptance of the design of our pivotal phase III trial and agreement on our CMC plan, Nanobiotix
Curadigm Announces Publication of Results Using Proprietary Nanoprimer to Improve RNA Therapeutics in Collaboration With the Langer Lab
Curadigm today announced the publication, with Prof. Robert Langer’s lab at MIT, of pre-clinical in vivo results showing that its Nanoprimer can improve the efficacy of RNA-based therapeutics. This
NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Nanobiotix Secures €10M in Non-Dilutive Financing
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020
Regulatory News:
NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Transgene: Combined General Meeting of May 27, 2020
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 27, 2020) at 10:00 a.m. at the Company's headquarters (400
Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)
Ipsen Announces Publication of First Matching-Adjusted Indirect Comparison of Cabometyx® (cabozantinib) Versus regorafenib in Advanced Hepatocellular Carcinoma in Advances in Therapy
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabozantinib) versus Stivarga® (regorafenib) for
Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s Powerful Activity Against Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”)
Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a
NANOBIOTIX Announces First Phase I Trial With NBTXR3 in Pancreatic Cancer Is Safe to Proceed Per US FDA
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Transgene Reports Q1 2020 Financial Position and Business Update
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses
Regulatory News:
Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s (Paris:TNG) proprietary DuckCelt®-T17 cell line.
NANOBIOTIX Announces First Quarter 2020 Revenues
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
EOS imaging Reports Its Full Year 2019 Results and First Quarter 2020 Revenues
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Alphatec Holdings Terminates Tender Offer Agreement with EOS imaging
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME) ("EOS"), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical
NANOBIOTIX Provides Updates on Clinical Development Continuity in the Context of the COVID-19 Crisis
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) today announced updates to the Company’s operational and global development plan in light of the
EOS imaging Announces the Rescheduling of the Publication of Its Annual Results
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and
Ipsen Provides Update on Palovarotene Clinical Programs
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will begin to reinitiate palovarotene dosing in patients 14 years of age and older currently participating in its
NANOBIOTIX 2019 Annual Results
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005789/en/
Pipeline (Graphic: NANOBIOTIX)
Transgene: Major R&D Milestones Achieved in 2019 and Strong Clinical Activity In 2020
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results
Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration
Regulatory News:
Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy
Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB